Neogen Chemicals Limited has informed the Exchange about Presentation
NEOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neogen Chemicals reported Q1 FY26 revenue of INR 184.6 crore (standalone, +5% YoY) and INR 186.7 crore (consolidated, +4% YoY). Standalone EBITDA rose 9% to INR 34.7 crore with margins improving to 18.8% (+74 bps), but consolidated EBITDA was largely flat at INR 31.5 crore with margins slipping to 16.9%. Standalone PAT grew 2% to INR 14.2 crore, while consolidated PAT fell 11% to INR 10.3 crore due to higher interest costs (up 48% standalone, 29% consolidated). The Dahej plant was unavailable for the entire quarter following the March 2025 fire, but Neogen Ionics began commercial sales of electrolytes and lithium salts, contributing INR 5.4 crore in revenue. Management adjusted near-term revenue guidance lower, though the long-term trajectory remains supported by a INR 1,500 crore CAPEX plan targeting peak revenue potential of INR 2,500-2,950 crore.
Mixed quarterly performance: standalone showed resilience through cost optimization, but consolidated profitability was hit by rising interest costs and the Dahej plant shutdown. Insurance inflows (INR 80.55 crore received so far) and CRISIL's rating reaffirmation are positives, but the downward revision of near-term guidance and a leadership transition at the top may weigh on sentiment in the short term.